NEW YORK (GenomeWeb News) – Cancer Research Technology, the technology commercialization arm of Cancer Research UK, said today that it will license certain intellectual property related to colorectal cancer risk assessment to the molecular diagnostics company ArcticDx.
 
Under the non-exclusive license agreement, ArcticDx will pay CRT an upfront payment and royalties from any sales of the biomarker-based test it plans to develop using the technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.